A 55 Y O Caucasian Male With Hypertension Type 2 Diabetes Obesity And Chal Abcvo Mory Of What We Primary Care Physican 1 (17.84 KiB) Viewed 57 times
A 55 Y O Caucasian Male With Hypertension Type 2 Diabetes Obesity And Chal Abcvo Mory Of What We Primary Care Physican 2 (9.82 KiB) Viewed 57 times
A 55 Y O Caucasian Male With Hypertension Type 2 Diabetes Obesity And Chal Abcvo Mory Of What We Primary Care Physican 3 (28.46 KiB) Viewed 57 times
A 55 y/o Caucasian male with hypertension type 2 diabetes, obesity, and chal ABCVO Mory of what we primary care physican Fasting laba include TC 235 mg/dL, TG 230 mg/dL, HDL 25 mg/dL, LDL, 165 mg/dl, and SOOS LAST GALT win lifestyle modifications, which is the most appropriate treatment for dyslipidemia management and ACVD reduction to Currently selected: A Lovastatin 40 mg daily В Rosuvastatin 40 mg daily с Atorvastatin 10 mg daily Simvastatin 80 mg daily
You have started a patient on torvastato ASCVD reduction today. When should you the Currently selected A 3 months B 3 days С 1 week 1 year
Which drug is matched with the correct clinical consideration in dyslipidemia? Currently selected A Cholestyramine-consider for treatment of hypertriglyceridemia and Asevd-rak teduction B Gemfibrozil - preferred agent to use with statin therapy for hypertriglyceridemia C Alirocumab-preferred agent with a history of rosuvastatin intolerance and tew HDL Ezetimibe - second-line agent for additional LDL lowering after maximizing statin therapy
Join a community of subject matter experts. Register for FREE to view solutions, replies, and use search function. Request answer by replying!
A Cholestyramine-consider for treatment of hypertriglyceridemia and Asevd-rak teduction B Gemfibrozil - preferred agent to use with statin therapy for hypertriglyceridemia C Alirocumab-preferred agent with a history of rosuvastatin intolerance and tew HDL Ezetimibe - second-line agent for additional LDL lowering after maximizing statin therapy